TNFSF13 and infection: A previous clinical study of atacicept, another APRIL inhibitor, showed two deaths due to infection in the 160 mg dosing group, suggesting that APRIL inhibition on top of BLyS may lead to hyperimmunosuppression, which increases the risk of infection23.